(CNO) CNO Financial - Ratings and Ratios
Health Insurance, Life Insurance, Annuities, Medicare Supplement, Long-Term Care
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.02% |
| Yield on Cost 5y | 4.35% |
| Yield CAGR 5y | 7.60% |
| Payout Consistency | 100.0% |
| Payout Ratio | 15.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.8% |
| Value at Risk 5%th | 40.4% |
| Relative Tail Risk | -1.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | -10.29 |
| CAGR/Max DD | 1.13 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.339 |
| Beta | 0.975 |
| Beta Downside | 1.169 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.12% |
| Mean DD | 6.00% |
| Median DD | 5.14% |
Description: CNO CNO Financial November 08, 2025
CNO Financial Group (NYSE:CNO) operates through subsidiaries to sell a suite of insurance and financial products-Medicare supplement, Medicare Advantage, long-term care, life insurance, and various annuities-targeting middle-income pre-retirees and retirees in the United States. Distribution channels include phone, virtual platforms, online portals, and face-to-face agents, with a notable focus on voluntary benefits sold at workplaces and through membership groups. The firm’s brands-Bankers Life, Washington National, and Colonial Penn-cover everything from fixed indexed annuities to universal and whole-life policies.
Key operational metrics from the most recent fiscal year (2023) show revenue of roughly $3.5 billion and an operating margin of ≈13 %, while the combined ratio for its health-insurance segment sits near 92 %, indicating underwriting profitability. The company benefits from macro-drivers such as the aging U.S. population (the 65-plus cohort is projected to grow 15 % over the next decade) and steady Medicare enrollment growth of about 3 % annually, both of which expand the addressable market for supplemental and Advantage products. Conversely, rising interest rates compress the yields on fixed-interest annuities, pressuring the profitability of that line.
For a deeper, data-rich assessment of CNO’s valuation dynamics, you may find ValueRay’s analytical dashboards useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (294.7m TTM) > 0 and > 6% of Revenue (6% = 266.5m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 0.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 317.2% (prev 1.45%; Δ 315.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 671.0m > Net Income 294.7m (YES >=105%, WARN >=100%) |
| Net Debt (2.83b) to EBITDA (934.9m) ratio: 3.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 390.2 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (98.6m) change vs 12m ago -6.19% (target <= -2.0% for YES) |
| Gross Margin 40.31% (prev 37.13%; Δ 3.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.70% (prev 12.00%; Δ -0.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.60 (EBITDA TTM 934.9m / Interest Expense TTM 239.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.76
| (A) 0.37 = (Total Current Assets 14.12b - Total Current Liabilities 36.2m) / Total Assets 38.30b |
| (B) 0.06 = Retained Earnings (Balance) 2.34b / Total Assets 38.30b |
| (C) 0.02 = EBIT TTM 622.1m / Avg Total Assets 37.97b |
| (D) 0.03 = Book Value of Equity 1.22b / Total Liabilities 35.69b |
| Total Rating: 2.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.83
| 1. Piotroski 3.50pt |
| 2. FCF Yield data missing |
| 3. FCF Margin 15.11% |
| 4. Debt/Equity 1.55 |
| 5. Debt/Ebitda 3.03 |
| 6. ROIC - WACC (= 0.62)% |
| 7. RoE 11.60% |
| 8. Rev. Trend 70.01% |
| 9. EPS Trend 59.31% |
What is the price of CNO shares?
Over the past week, the price has changed by +3.81%, over one month by +2.49%, over three months by +5.37% and over the past year by +3.42%.
Is CNO a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 4
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CNO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.4 | 7.8% |
| Analysts Target Price | 44.4 | 7.8% |
| ValueRay Target Price | 48.3 | 17.3% |
CNO Fundamental Data Overview November 26, 2025
P/E Trailing = 13.9829
P/E Forward = 9.7087
P/S = 0.8911
P/B = 1.4772
P/EG = 1.58
Beta = 0.874
Revenue TTM = 4.44b USD
EBIT TTM = 622.1m USD
EBITDA TTM = 934.9m USD
Long Term Debt = 4.05b USD (from longTermDebt, last quarter)
Short Term Debt = 2.44b USD (from shortTermDebt, two quarters ago)
Debt = 4.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.83b USD (from netDebt column, last quarter)
Enterprise Value = -590.0m USD (3.96b + Debt 4.05b - CCE 8.60b)
Interest Coverage Ratio = 2.60 (Ebit TTM 622.1m / Interest Expense TTM 239.7m)
FCF Yield = -113.7% (FCF TTM 671.0m / Enterprise Value -590.0m)
FCF Margin = 15.11% (FCF TTM 671.0m / Revenue TTM 4.44b)
Net Margin = 6.64% (Net Income TTM 294.7m / Revenue TTM 4.44b)
Gross Margin = 40.31% ((Revenue TTM 4.44b - Cost of Revenue TTM 2.65b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 38.92%)
Tobins Q-Ratio = -0.02 (set to none) (Enterprise Value -590.0m / Total Assets 38.30b)
Interest Expense / Debt = 1.40% (Interest Expense 56.6m / Debt 4.05b)
Taxrate = 36.19% (13.1m / 36.2m)
NOPAT = 397.0m (EBIT 622.1m * (1 - 36.19%))
Current Ratio = 390.2 (out of range, set to none) (Total Current Assets 14.12b / Total Current Liabilities 36.2m)
Debt / Equity = 1.55 (Debt 4.05b / totalStockholderEquity, last quarter 2.61b)
Debt / EBITDA = 3.03 (Net Debt 2.83b / EBITDA 934.9m)
Debt / FCF = 4.22 (Net Debt 2.83b / FCF TTM 671.0m)
Total Stockholder Equity = 2.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.77% (Net Income 294.7m / Total Assets 38.30b)
RoE = 11.60% (Net Income TTM 294.7m / Total Stockholder Equity 2.54b)
RoCE = 9.44% (EBIT 622.1m / Capital Employed (Equity 2.54b + L.T.Debt 4.05b))
RoIC = 5.82% (NOPAT 397.0m / Invested Capital 6.82b)
WACC = 5.20% (E(3.96b)/V(8.01b) * Re(9.61%) + D(4.05b)/V(8.01b) * Rd(1.40%) * (1-Tc(0.36)))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.86%
[DCF Debug] Terminal Value 74.02% ; FCFE base≈648.0m ; Y1≈698.5m ; Y5≈861.0m
Fair Price DCF = 120.1 (DCF Value 11.46b / Shares Outstanding 95.4m; 5y FCF grow 8.78% → 3.0% )
EPS Correlation: 59.31 | EPS CAGR: 11.08% | SUE: 2.06 | # QB: 1
Revenue Correlation: 70.01 | Revenue CAGR: 2.72% | SUE: 0.95 | # QB: 1
Additional Sources for CNO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle